References
- Lievertz R W. Pharmacology and pharmacokinetics of estrogens. Am J Obstet Gynecol 1987; 156: 1289–93
- Judd H L. Oestrogen replacement therapy: physiological considerations and new applications. Bailliere's Clin Endocrinol Metab 1987; 1: 177–206
- Kuhnz W, Gansau C, Mahler M. Pharmaco-kinetics of estradiol, free and total estrone, in young women following single intravenous and oral administration of 17β-estradiol. Arzneim Forsch 1993; 43: 966–73
- Steingold K A, Laufer L, Chetkowski R J, et al. Treatment of hot flashes with transdermal estradiol treatment. J Clin Endocrinol Metab 1985; 61: 627–32
- Selby P L, McGarricle H HG, Peacock M. Comparison of the effects of oral and transdermal oestradiol administration on oestrogen metabolism, protein synthesis, gonadotrophin release, bone turnover and climacteric symptoms in postmenopausal women. Clin Endocrinol 1989; 30: 241–9
- Marty J P. New trends in transdermal technologies: development of the skin patch, Menorest®. Int J Gynecol Obstet 1996; 52: 17–20
- Balfour J, Heel R. Transdermal estradiol. A review of its pharmacodynamic properties, and therapeutic efficacy in the treatment of postmenopausal complaints. Drugs 1990; 40: 561–82
- Reginster J Y, Albert A, Deroisy R, et al. Plasma estradiol concentrations and pharmacokinetics following transdermal application of Menorest® 50 or Systen® (Evorel®) 50. Maturitas 1997; 27: 179–86
- Berner B, John V A. Pharmacokinetic characterisation of transdermal delivery systems. Clin Pharmacokinet 1994; 26: 121–34
- Johnson W. Amended final report on the safety assessment of hydroxystearic acid. Int J Toxicol 1999; 18: 1–10
- Walters K A. Penetration enhancers and their use in transdermal therapeutic systems. Drugs Pharmaceutical Sciences - Transdermal Drug Delivery, J Hadgraft, R H Guy. Marcel Dekker, New York 1989; 35: 197–246
- Rohr U D, Nauert C, Stehle B. 17β-Estradiol delivered by three different matrix patches 50 μg/day. A three way cross-over study in 21 postmenopausal women. Maturitas 1999; 33: 45–58
- O'Connell M B. Pharmacokinetic and pharmacologic variation between different estrogen products. J Clin Pharmacol 1995; 35: 18S–24S
- Müller P, Botta L, Ezzet F. Bioavailability of estradiol from a new matrix and a conventional reservoir–type transdermal therapeutic system. Eur J Clin Pharmacol 1996; 51: 327–30
- Le Roux Y, Borg M L, Thebault J, et al. Bioavailability study of Menorest®, a new estrogen transdermal delivery system, compared with a transdermal reservoir system. Clin Drug Invest 1995; 10: 172–8
- Setnikar I, Rovati L C, Vens-Cappell B, et al. Bioavailability of estradiol from two transdermal patches. Arzneim Forsch 1996; 46: 307–10
- The Transdermal HRT Investigators Group. A randomized study to compare the effectiveness, tolerability and acceptability of two different transdermal replacement therapies. Int J Fertil 1993; 38: 5–11